Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 3/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.51 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469488 | 1.00 | HTR3A (0.52) | HTR3ACRBNHTR3BADRA2AKCNE1 | |
| SCHEMBL4074347 | 0.84 | HTR3A (0.52) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL4087446 | 0.82 | HTR3A (0.56) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL29607124 | 0.80 | HTR3A (0.48) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL4074754 | 0.79 | HTR3A (0.53) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL12714378 | 0.78 | CRBN (0.53) | CRBN | |
| SCHEMBL12714376 | 0.78 | CRBN (0.53) | CRBN | |
| SCHEMBL6575375 | 0.78 | HTR3A (0.48) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL6575344 | 0.78 | HTR3A (0.48) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| SCHEMBL6575349 | 0.78 | HTR3A (0.48) | HTR3AHTR3BADRA2AKCNE1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076291-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-03-07 | — | — | US | disclosed |
| EP-4251149-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2022115301-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115301-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076291-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | HTR3A 3897/4885CRBN 3621/4885HTR3B 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.